# Alexander Fleming

415.999.9999 | Alexander.Fleming@ucsf.edu

## **OUALIFICATIONS SUMMARY**

- Over 3 years of experience in clinical pharmacology, drug development, and PK/PD
- Excellent communication and presentation skills for a broad audience having authored and presented various national and international studies
- Strong expertise in analyzing and interpreting clinical data from Phase I-III trials through deep understanding of Phoenix NLME and NONMEM software

#### DRUG DEVELOPMENT EXPERIENCE

Clinical PK Scientist (Oncology – Small Molecules)

(Month Year – Present)

- Science Co.1 | xxx, CA
- Analyze PK/PD data through simulation tools to impact decisions in dose escalation for oncology patients
- Lead 2 major oncology Phase I/II programs which included interpreting and presenting PK/PD data to senior management enabling cohort escalation and expansion decisions
- Plan and review study designs and analysis plans for Phase I-III studies

#### **Clinical Research Pharmacist**

(Month Year – Month Year)

University of California, San Francisco (UCSF) – School of Pharmacy | San Francisco, CA

- Assisted with all aspects of investigational drug supply and medication dispensing for 3 clinical trials through meticulously maintaining study protocols, documentation requirements, and DEA/FDA guidelines
- Participated as a key team member by collaborating and communicating with researchers and senior staff to clarify goals, identify study subject parameters, and potential complications

# Clinical Pharmacology Consultant (Oncology – Large Molecules)

(Month Year – Month Year)

Science Co.2 | xxx, CA

- Guided protocol development for PK bridging study in x-country with global cross-functional teams
- Simulated, interpreted, and presented preliminary PK data for clinical study team meetings to enable doseescalation decision on a high priority xxx program which aided in granting breakthrough therapy designation by the FDA
- Prepared regulatory documents for filing of a New Drug Application (NDA)

### POST-DOCTORAL FELLOWSHIP EXPERIENCE

# Pharmacokineticist I – Post-Doctoral Fellow in Clinical PK/PD

(Month Year – Month Year)

Science Co.3 | xxx, CA

- Facilitated development of protocols and study reports in x-number of studies in the US and globally
- Reviewed PK/PD data for multiple studies, including drug-drug interaction, relative bioavailability, absolute bioavailability using microtracer IV dose, and bioequivalence
- Presented PK/PD study results and conclusions to Pharma clients in study closeout meetings

# Post-Doctoral Fellow in Clinical PK/PD

(Month Year – Month Year)

University of California, San Francisco (UCSF) – School of Pharmacy | San Francisco, CA

- Designed and implemented a three-way crossover clinical drug-drug interaction study to understand the contribution of direct *X-xxx* to xxx probe xxx in healthy human volunteers
- Performed the role of a clinical study coordinator and drove trial to completion within 3 months
- Developed the clinical study protocol, consent forms, and recruited subjects
- Generated and presented clinical data at ACCP Clinical Pharmacology Conference and received the Pharmacology Innovative Research Award
- Developed a clinical study in post-cardiac arrest patients to ascertain the impact of therapeutic xxx on the absorption and metabolism of drug x through obtaining a \$5,000 fund from the ACCP Research Institute **Futures Grant**

#### **AWARDS & RECOGNITION**

Presidential Trainee Award, American Society for Clinical Pharmacy	(Month Year)
Pharmacology and Therapeutics Award, American Society for Clinical Pharmacology	(Month Year)
Clinical Research Award, UCSF	(Month Year)
National Science Foundation Fellowship, National Science Foundation	(Month Year)
Dean's Public Service Award, UCSF	(Month Year)

#### **CERTIFICATIONS**

California State Board of Pharmacy Licensure

(Month Year – Present)

### PROFESSIONAL LEADERSHIP & SERVICE

American College of Clinical Pharmacy (ACCP) President, UCSF Chapter	(Month Year – Month Year)
International Society of Pharmacometrics (ISoP) Member	(Month Year – Month Year)
American College of Clinical Pharmacology Member	(Month Year – Month Year)
Antibiotic Resistance Project Coordinator, UCSF	(Month Year – Month Year)
Children's Health Hut Health Fair Volunteer, UCSF	(Month Year – Month Year)

#### **EDUCATION**

<b>Doctor of Pharmacy,</b> University of California, San Francisco	Month Year (Graduation Date)
Bachelor of Sciences, Biochemistry, University of California, Davis	Month Year (Graduation Date)

#### **PRESENTATIONS**

Paul Ehrlich, Alexander Fleming, and Robert Koch. Penicillin. UCSF Student Medical Society. Month, Year.

Paul Ehrlich, **Alexander Fleming**, Robert Koch, and Anton van Leeuwenhoek. *The Combination of Immunity with Chemotherapy*. UCSF Medical Center [abstract]. Month, Year.

**Alexander Fleming.** *Recent Progress in Antibiotics.* Lectures on the Scientific Basis of Medicine, vol. II. British Postgraduate Pharmacology Association. Month, Year.

Alexander Fleming. Physiologically-Based Pharmacokinetic Penicillin Interactions. Month, Year.

#### **PUBLICATIONS**

Alexander Fleming. Problems in the Titration of Streptomycin. British Medical Journal. Month, Year.

Paul Ehrlich, **Alexander Fleming**, Robert Koch, and Anton van Leeuwenhoek. *The Discovery of Penicillin*. British Medical Bulletin, vol. 2. Month, Year.

Paul Ehrlich, **Alexander Fleming**, Robert Koch, and Anton van Leeuwenhoek. *Penicillin for the British War Medicine Reviews*. Anglo Soviet Medical Committee. Month, Year.

Paul Ehrlich, **Alexander Fleming**, Robert Koch, and Anton van Leeuwenhoek. On the *Antibacterial Action of Cultures of Penicillium*, with Special Reference to their use in the Isolation of B. Influenzae. British Journal of Experimental Pathology. Month, Year.

#### IN SUBMISSION

Paul Ehrlich and **Alexander Fleming.** *The English Experiment*. (submitted to the American Journal of Pharmacy)

Paul Ehrlich and **Alexander Fleming.** *Influence of Penicillin on the Coagulation of Blood with Especial Reference to Certain Dental Operations.* (submitted to the British Medical Journal)